Neuroanatomical predictors of L-DOPA response in older adults with psychomotor slowing and depression: A pilot study.
Gait speed
Late life depression
Levodopa
Magnetic resonance imaging
Processing speed
Journal
Journal of affective disorders
ISSN: 1573-2517
Titre abrégé: J Affect Disord
Pays: Netherlands
ID NLM: 7906073
Informations de publication
Date de publication:
15 03 2020
15 03 2020
Historique:
received:
11
10
2019
revised:
07
01
2020
accepted:
15
01
2020
entrez:
25
2
2020
pubmed:
25
2
2020
medline:
16
2
2021
Statut:
ppublish
Résumé
Declining function in dopamine circuits is implicated in normal aging and late-life depression (LLD). Dopamine augmentation recently has shown therapeutic promise, but predictors of response are unknown. Depressed elders with slowed gait underwent baseline magnetic resonance imaging (MRI) and [ Among N = 16 participants aged 72.5 ± 6.8 years, higher left superior temporal gyrus volume was associated with higher processing speed at baseline, while cortical thinning in a processing speed network was associated with greater improvement following L-DOPA. Greater volume and cortical thickness in brain regions associated with mobility were associated with higher baseline gait speed. Higher baseline white matter hyperintensity volume predicted less post-L-DOPA improvement on dual task gait speed and IDS-SR scores. Higher [ Limiting the conclusions drawn from this pilot study are the small sample size and open administration of L-DOPA. Greater baseline brain volumes and cortical thickness in regions supporting cognition and gait were associated with higher behavioral performance, while lower structural integrity was associated with increased responsivity to L-DOPA. If substantiated in larger studies, these findings could facilitate the targeting of dopaminergic treatments to those LLD patients most likely to respond.
Sections du résumé
BACKGROUND
Declining function in dopamine circuits is implicated in normal aging and late-life depression (LLD). Dopamine augmentation recently has shown therapeutic promise, but predictors of response are unknown.
METHODS
Depressed elders with slowed gait underwent baseline magnetic resonance imaging (MRI) and [
RESULTS
Among N = 16 participants aged 72.5 ± 6.8 years, higher left superior temporal gyrus volume was associated with higher processing speed at baseline, while cortical thinning in a processing speed network was associated with greater improvement following L-DOPA. Greater volume and cortical thickness in brain regions associated with mobility were associated with higher baseline gait speed. Higher baseline white matter hyperintensity volume predicted less post-L-DOPA improvement on dual task gait speed and IDS-SR scores. Higher [
LIMITATIONS
Limiting the conclusions drawn from this pilot study are the small sample size and open administration of L-DOPA.
CONCLUSIONS
Greater baseline brain volumes and cortical thickness in regions supporting cognition and gait were associated with higher behavioral performance, while lower structural integrity was associated with increased responsivity to L-DOPA. If substantiated in larger studies, these findings could facilitate the targeting of dopaminergic treatments to those LLD patients most likely to respond.
Identifiants
pubmed: 32090770
pii: S0165-0327(19)32807-1
doi: 10.1016/j.jad.2020.01.066
pmc: PMC7042346
mid: NIHMS1552678
pii:
doi:
Substances chimiques
Raclopride
430K3SOZ7G
Levodopa
46627O600J
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
439-444Subventions
Organisme : NIMH NIH HHS
ID : R33 MH110029
Pays : United States
Organisme : NIMH NIH HHS
ID : R61 MH110029
Pays : United States
Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2020. Published by Elsevier B.V.
Références
Am J Geriatr Psychiatry. 2008 Jan;16(1):65-73
pubmed: 17998306
J Clin Psychiatry. 1996;57 Suppl 5:5-11
pubmed: 8647792
Am J Psychiatry. 2012 Nov;169(11):1185-93
pubmed: 23534057
Hum Brain Mapp. 2015 Apr;36(4):1484-93
pubmed: 25504964
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
J Gerontol A Biol Sci Med Sci. 2016 Feb;71(2):221-7
pubmed: 26392405
Biol Psychiatry. 2019 Aug 1;86(3):221-229
pubmed: 31178096
PLoS One. 2013 Jul 09;8(7):e68632
pubmed: 23874698
Int J Geriatr Psychiatry. 2012 Sep;27(9):893-9
pubmed: 22009869
JAMA. 1992 Aug 26;268(8):1018-24
pubmed: 1501308
Ann Neurol. 1998 Jul;44(1):143-7
pubmed: 9667606
J Geriatr Psychiatry Neurol. 2014 Mar;27(1):24-32
pubmed: 24381231
Neuroimage Clin. 2019;21:101636
pubmed: 30558868
J Gerontol A Biol Sci Med Sci. 2009 Aug;64(8):896-901
pubmed: 19349593
Arch Gen Psychiatry. 2004 Jun;61(6):587-95
pubmed: 15184238
Int J Geriatr Psychiatry. 2009 Aug;24(8):829-36
pubmed: 19551696
Arch Gen Psychiatry. 2010 Mar;67(3):277-85
pubmed: 20194828
J Nutr Health Aging. 2009 Dec;13(10):881-9
pubmed: 19924348
J Affect Disord. 2011 Dec;135(1-3):315-20
pubmed: 21802739
Clin Neuropsychol. 2018 Jan-Dec;32(sup1):114-132
pubmed: 29911493
Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5108-5117
pubmed: 30796187
Neuropsychopharmacology. 2004 Jun;29(6):1190-202
pubmed: 15010698
Trends Cogn Sci. 1998 Nov 1;2(11):436-47
pubmed: 21227275
J Cogn Neurosci. 2015 Jun;27(6):1249-58
pubmed: 25539045
Int J Geriatr Psychiatry. 2014 Dec;29(12):1173-84
pubmed: 24798480
J Cereb Blood Flow Metab. 2006 Sep;26(9):1198-212
pubmed: 16421508
Arch Gen Psychiatry. 1996 Apr;53(4):305-12
pubmed: 8634008
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Neurotherapeutics. 2011 Jan;8(1):72-81
pubmed: 21274687
Neurosci Biobehav Rev. 2006;30(1):1-23
pubmed: 15935475
Neuroimage. 2004;23 Suppl 1:S69-84
pubmed: 15501102
Front Hum Neurosci. 2017 Aug 03;11:353
pubmed: 28824393